4.4 Article

Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations

期刊

DIABETES TECHNOLOGY & THERAPEUTICS
卷 23, 期 -, 页码 S5-S11

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2021.0236

关键词

Integrated CGM; Accuracy; MARD; FDA; Class II; Class III devices

资金

  1. Abbott Diabetes Care

向作者/读者索取更多资源

Continuous glucose monitoring devices have been significantly improved with better sensor accuracy, leading to FDA approval of nonadjunctive use. This is important for informed clinical decision-making regarding current systems' performance characteristics and regulatory classifications.
Continuous glucose monitoring devices have significantly improved in many respects compared with earlier versions. As sensor accuracy improved, U.S. Food and Drug Administration approved a nonadjunctive indication for use that no longer required confirmatory blood glucose monitoring. This article discusses the performance characteristics and regulatory classifications for the current systems that are relevant to informed clinical decision-making.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial

Tadej Battelino, Ramin Tehranchi, Timothy Bailey, Klemen Dovc, Anita Melgaard, Jenine Yager Stone, Stephanie Woerner, Thekla von Dem Berge, Linda DiMeglio, Thomas Danne

Summary: In a trial involving pediatric individuals with type 1 diabetes experiencing insulin-induced hypoglycemia, dasiglucagon proved to be more effective in restoring blood glucose levels compared to placebo, with a safety profile similar to glucagon.

PEDIATRIC DIABETES (2021)

Article Endocrinology & Metabolism

Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial

Timothy S. Bailey, Julie Willard, Leslie J. Klaff, Jenine Yager Stone, Anita Melgaard, Ramin Tehranchi

Summary: Dasiglucagon administered via an autoinjector device provided rapid reversal of hypoglycaemia in adults with type 1 diabetes, with no serious adverse events reported. The aqueous formulation of dasiglucagon in a ready-to-use autoinjector device may offer a reliable treatment option for severe hypoglycaemia.

DIABETES OBESITY & METABOLISM (2021)

Article Endocrinology & Metabolism

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study

Satish K. Garg, David Liljenquist, Bruce Bode, Mark P. Christiansen, Timothy S. Bailey, Ronald L. Brazg, Douglas S. Denham, Anna R. Chang, Halis Akturk, Andrew Dehennis, Katherine S. Tweden, Francine R. Kaufman

Summary: The PROMISE study evaluated the accuracy and safety of the next-generation implantable Eversense CGM system for up to 180 days. The results showed sustained accuracy and safety of the system, with improved calibration scheme and sensor survival, using either primary or SBA sensors.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes

Satish K. Garg, Mark Kipnes, Kristin Castorino, Timothy S. Bailey, Halis Kaan Akturk, John B. Welsh, Mark P. Christiansen, Andrew K. Balo, Sue A. Brown, Jennifer L. Reid, Stayce E. Beck

Summary: The study evaluated the accuracy and safety of a seventh generation Dexcom CGM in adults with diabetes. Results showed single-digit MARD values with sensors placed on the arm or abdomen, indicating high accuracy.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia

Naila Celeste Bailey, Jeannett Dimsits, Mette Hammer, David M. Kendall, Timothy S. Bailey

Summary: In the study, it was found that trained caregivers and untrained bystanders were able to administer the dasiglucagon autoinjector more rapidly and with greater ease compared to the Eli Lilly GEK, resulting in higher user satisfaction.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study

Timothy S. Bailey, Jasvinder Gill, Merwyn S. Jones, Laxmi Shenoy, Charlie Nicholls, Jukka Westerbacka

Summary: Adding insulin glargine 300 U/mL (Gla-300) to GLP-1RA therapy significantly improved glycemic control without increasing the risk of hypoglycemia in patients with type 2 diabetes.

DIABETES OBESITY & METABOLISM (2022)

Article Endocrinology & Metabolism

Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial

Ron Brazg, Satish K. Garg, Anuj Bhargava, James R. Thrasher, Kashif Latif, Bruce W. Bode, Timothy S. Bailey, Barry S. Horowitz, Arvind Cavale, Yogish C. Kudva, Kevin B. Kaiserman, George Grunberger, John Chip Reed, Sarnath Chattaraj, Gina Zhang, John Shin, Vivian Chen, Scott W. Lee, Toni L. Cordero, Andrew S. Rhinehart, Robert A. Vigersky, Bruce A. Buckingham

Summary: This trial evaluated the safety and performance of a new extended-wear infusion set when used for 7 days by adults with type 1 diabetes. The results showed that the extended-wear infusion set was safe and rated with high satisfaction by patients, without adversely affecting glycemic control.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes

Lori M. Laffel, Timothy S. Bailey, Mark P. Christiansen, Jennifer L. Reid, Stayce E. Beck

Summary: The accuracy of the G7 continuous glucose monitoring system was evaluated in children and adolescents with type 1 diabetes. The results showed that the system was accurate in various age groups and situations, whether the sensor was placed on the arm or abdomen.

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY (2023)

Review Endocrinology & Metabolism

Insulin Titration Guidelines for Patients With Type 1 Diabetes: It Is About Time!

John Walsh, Ruth Roberts, Timothy S. Bailey, Lutz Heinemann

Summary: This study proposes the establishment of an Insulin Advisory Committee to develop insulin titration guidelines 100 years after its discovery. Despite significant advances in diabetes technology, glucose control metrics remain poor. The lack of clear insulin titration guidelines has led to inefficiencies in reaching recommended glycemic goals, with healthcare providers and patients managing insulin titrations as they see fit. This review details the widespread problems in current insulin delivery devices and presents a method for optimized total daily doses of insulin to address hyperglycemia.

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY (2023)

Editorial Material Biochemistry & Molecular Biology

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

Jeremy Pettus, Schafer C. Boeder, Mark P. Christiansen, Douglas S. Denham, Timothy S. Bailey, Halis K. Akturk, Leslie J. Klaff, Julio Rosenstock, Mickie H. M. Cheng, Bruce W. Bode, Edgar D. Bautista, Ren Xu, Hai Yan, Thai Dung, Satish K. Garg, Samuel Klein

Summary: This study evaluated the safety and efficacy of volagidemab, an antagonistic monoclonal glucagon receptor antibody, as an adjunct to insulin therapy in patients with type 1 diabetes. The results showed that volagidemab reduced daily insulin use and decreased HbA1c levels. However, further research is needed to confirm the long-term efficacy and safety of volagidemab.

NATURE MEDICINE (2022)

Article Endocrinology & Metabolism

Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes

Simon Heller, Tadej Battelino, Timothy S. Bailey, Thomas R. Pieber, Ulrike Hoevelmann, Leona Plum-Moerschel, Anita E. Melgaard, Ronnie Aronson, Linda A. DiMeglio, Thue Johansen, Thomas Danne

Summary: This study analyzed the safety and efficacy of dasiglucagon, a glucagon analogue, in treating severe hypoglycemia in patients with type 1 diabetes. The results showed that dasiglucagon had a similar safety profile as reconstituted glucagon and was more effective in glucose recovery compared to placebo.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear

Jasmin R. Kastner, Timothy S. Bailey, Poul Strange, Leon Shi, Keith A. Oberg, Paul J. Strasma, Jeffrey I. Joseph, Douglas B. Muchmore

Summary: Insulin exposure varies over the course of insulin infusion set (IIS) wear, posing challenges for insulin dosing in people with diabetes. This study extends previous observations by examining 7 days of IIS wear and reports insulin pharmacodynamic and pharmacokinetic data. The results show progressive decreases in insulin t(max), C-max, and mean residence time, as well as a decline in the area under the insulin concentration curve (AUC(0-300)). These findings have implications for individuals with diabetes and the development of closed-loop algorithms, although further research is needed to confirm these findings. The study was registered in clinicaltrials.gov (NCT04398030).

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Correction Biochemistry & Molecular Biology

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial (vol 28, pg 2092, 2022)

Jeremy Pettus, Schafer C. Boeder, Mark P. Christiansen, Douglas S. Denham, Timothy S. Bailey, Halis K. Akturk, Leslie J. Klaff, Julio Rosenstock, Mickie H. M. Cheng, Bruce W. Bode, Edgar D. Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K. Garg, Samuel Klein

NATURE MEDICINE (2023)

Article Endocrinology & Metabolism

Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System

Shridhara Alva, Ronald Brazg, Kristin Castorino, Mark Kipnes, David R. Liljenquist, Hanqing Liu

Summary: This study evaluated the performance of the FreeStyle Libre (R) 3 continuous glucose monitoring system (FSL3) and compared it to different reference glucose values. The results showed that the FSL3 demonstrated accurate performance during the 14-day sensor wear period.

DIABETES THERAPY (2023)

Article Endocrinology & Metabolism

Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes

Shridhara Alva, Timothy Bailey, Ronald Brazg, Erwin S. Budiman, Kristin Castorino, Mark P. Christiansen, Gregory Forlenza, Mark Kipnes, David R. Liljenquist, Hanqing Liu

Summary: This study evaluated the analytical performance of the second-generation factory-calibrated FreeStyle Libre 2 system compared to the YSI reference. The results showed that the system performed well in terms of accuracy and bias during the 14-day sensor wear period. It demonstrated excellent performance in the hypoglycemic range.

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY (2022)

暂无数据